MedPath

ate Phase II study of Paricalcitol injectio

Phase 2
Conditions
Secondary Hyperparathyroidism
Registration Number
JPRN-jRCT2080220559
Lead Sponsor
Abbott Japan Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Aged 20 or over
Chronic kidney disease subjects receiving hemodialysis with secondary hyperparathyroidism

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath